GU Cancers 2022 | URO-12: Importance of collaboration between institutions in clinical trials

Name: URO-12: Importance of collaboration between institutions in clinical trials
Uploaded: 2022-03-03T00:00:00Z
Duration: 1 min 18 s
Description: Massimo Di Maio, PhD, University of Turin, Turin, Italy, discusses the challenges that the URO-12 trial faced, and how collaboration between instituitions helped to overcome these difficulties. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

Massimo Di Maio • 3 Mar 2022

GU Cancers 2022

Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Avelumab Niraparib

URO-12

Massimo Di Maio, PhD, University of Turin, Turin, Italy, discusses the challenges that the URO-12 trial faced, and how collaboration between instituitions helped to overcome these difficulties. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

Disclosures

Massimo Di Maio reports personal fees from AstraZeneca, Pfizer, Novartis, Roche, Takeda, Janssen, Eisai, Astellas, Merck Sharp & Dohme, Boehringer Ingelheim, research grant from Tesaro – GlaxoSmithKline.